Mucosal Immunology, ISSN 1933-0219, 03/2013, Volume 6, Issue 2, pp. 427 - 434
Cervical and vaginal epithelia are primary barriers against HIV type I (HIV-1) entry during male-to-female transmission. Cervical mucus (CM) is produced by the...
MENSTRUAL-CYCLE | WOMEN | HUMAN CERVICAL-MUCUS | MUCIN | DRUG-DELIVERY | HUMAN ENDOCERVIX | IMMUNOLOGY | PROTEINS | SPERM PENETRABILITY | BACTERIAL VAGINOSIS | MOLECULES | Cervix Mucus - immunology | Cell Line | Cervix Mucus - virology | Humans | Virion - physiology | Facilitated Diffusion | Male | HIV-1 - physiology | Biological Transport | Female | Semen - virology | Semen - physiology | Cervix Mucus - physiology | Hydrogen-Ion Concentration
MENSTRUAL-CYCLE | WOMEN | HUMAN CERVICAL-MUCUS | MUCIN | DRUG-DELIVERY | HUMAN ENDOCERVIX | IMMUNOLOGY | PROTEINS | SPERM PENETRABILITY | BACTERIAL VAGINOSIS | MOLECULES | Cervix Mucus - immunology | Cell Line | Cervix Mucus - virology | Humans | Virion - physiology | Facilitated Diffusion | Male | HIV-1 - physiology | Biological Transport | Female | Semen - virology | Semen - physiology | Cervix Mucus - physiology | Hydrogen-Ion Concentration
Journal Article
1985, Handbook of experimental pharmacology, ISBN 3540152598, Volume 78., xiv, 451
Book
The New England Journal of Medicine, ISSN 0028-4793, 02/2017, Volume 376, Issue 7, pp. 617 - 628
This study assessed survival and neurodevelopmental outcomes among infants born at 22 to 24 weeks of gestation, as measured at 18 to 22 months of corrected...
MORTALITY | MEDICINE, GENERAL & INTERNAL | NATIONAL INSTITUTE | BIRTH-WEIGHT INFANTS | MORBIDITY | CHILDREN BORN | EXTREMELY PRETERM INFANTS | WEEKS GESTATIONAL-AGE | SCALES | ACTIVE PERINATAL-CARE | BAYLEY-III | Neurodevelopmental Disorders - epidemiology | United States - epidemiology | Cerebral Palsy - epidemiology | Hearing Loss - epidemiology | Humans | Infant | Male | Survival Rate | Infant, Premature, Diseases - mortality | Incidence | Neuropsychological Tests | Maternal Age | Female | Infant, Extremely Premature | Vision Disorders - epidemiology | Infant Mortality - trends | Infant, Newborn | Analysis | Patient outcomes | Survival after airplane accidents, shipwrecks, etc | Nervous system | Infants | Degeneration | Health aspects | Neonates | Premature birth | Childrens health | Infant mortality | Gestation | Neurodevelopmental disorders | Survival | Babies | Survival analysis | Child development | Risk assessment | Death | Children | Developmental disabilities
MORTALITY | MEDICINE, GENERAL & INTERNAL | NATIONAL INSTITUTE | BIRTH-WEIGHT INFANTS | MORBIDITY | CHILDREN BORN | EXTREMELY PRETERM INFANTS | WEEKS GESTATIONAL-AGE | SCALES | ACTIVE PERINATAL-CARE | BAYLEY-III | Neurodevelopmental Disorders - epidemiology | United States - epidemiology | Cerebral Palsy - epidemiology | Hearing Loss - epidemiology | Humans | Infant | Male | Survival Rate | Infant, Premature, Diseases - mortality | Incidence | Neuropsychological Tests | Maternal Age | Female | Infant, Extremely Premature | Vision Disorders - epidemiology | Infant Mortality - trends | Infant, Newborn | Analysis | Patient outcomes | Survival after airplane accidents, shipwrecks, etc | Nervous system | Infants | Degeneration | Health aspects | Neonates | Premature birth | Childrens health | Infant mortality | Gestation | Neurodevelopmental disorders | Survival | Babies | Survival analysis | Child development | Risk assessment | Death | Children | Developmental disabilities
Journal Article
American Heart Journal, ISSN 0002-8703, 2010, Volume 160, Issue 5, pp. 785 - 794.e10
Background Lowering low-density lipoprotein (LDL) cholesterol with statin therapy has been shown to reduce the incidence of atherosclerotic events in many...
Cardiovascular | UNITED-KINGDOM HEART | METAANALYSIS | REQUIRING PROLONGED OBSERVATION | EFFICACY | CARDIOVASCULAR OUTCOMES | SAFETY | CLINICAL-TRIALS | SIMVASTATIN | EZETIMIBE | STATINS | UMCG Approved | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | Simvastatin - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Ezetimibe | Male | Incidence | Dose-Response Relationship, Drug | Atherosclerosis - etiology | Adult | Cholesterol, LDL - blood | Female | Retrospective Studies | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Cholesterol, LDL - drug effects | Treatment Outcome | Atherosclerosis - blood | Kidney Failure, Chronic - therapy | Anticholesteremic Agents - therapeutic use | Azetidines - administration & dosage | Azetidines - therapeutic use | Kidney Failure, Chronic - blood | Anticholesteremic Agents - administration & dosage | Kidney Failure, Chronic - complications | Aged | Atherosclerosis - prevention & control | Renal Dialysis | Medicine, Experimental | Medical research | Chronic kidney failure | Analysis | Low density lipoproteins | Cholesterol | Lipids | Heart attacks | Drug therapy | Low density lipoprotein | Clinical Medicine | Urologi och njurmedicin | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Urology and Nephrology
Cardiovascular | UNITED-KINGDOM HEART | METAANALYSIS | REQUIRING PROLONGED OBSERVATION | EFFICACY | CARDIOVASCULAR OUTCOMES | SAFETY | CLINICAL-TRIALS | SIMVASTATIN | EZETIMIBE | STATINS | UMCG Approved | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | Simvastatin - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Ezetimibe | Male | Incidence | Dose-Response Relationship, Drug | Atherosclerosis - etiology | Adult | Cholesterol, LDL - blood | Female | Retrospective Studies | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Cholesterol, LDL - drug effects | Treatment Outcome | Atherosclerosis - blood | Kidney Failure, Chronic - therapy | Anticholesteremic Agents - therapeutic use | Azetidines - administration & dosage | Azetidines - therapeutic use | Kidney Failure, Chronic - blood | Anticholesteremic Agents - administration & dosage | Kidney Failure, Chronic - complications | Aged | Atherosclerosis - prevention & control | Renal Dialysis | Medicine, Experimental | Medical research | Chronic kidney failure | Analysis | Low density lipoproteins | Cholesterol | Lipids | Heart attacks | Drug therapy | Low density lipoprotein | Clinical Medicine | Urologi och njurmedicin | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Urology and Nephrology
Journal Article
Mucosal Immunology, ISSN 1933-0219, 11/2016, Volume 9, Issue 6, pp. 1549 - 1558
Transmission of HIV across mucosal barriers accounts for the majority of HIV infections worldwide. Thus, efforts aimed at enhancing protective immunity at...
RESPONSES | FC-GAMMA-RIII | SURFACE | IMMUNOGLOBULIN | GLYCOFORMS | IGG-FC | GLYCOSYLATION | IMMUNOLOGY | EXPRESSION | VIRION CAPTURE | ANTIGEN | HIV Antibodies - metabolism | CA-125 Antigen - immunology | Mucous Membrane - virology | Immunoglobulin Fc Fragments - metabolism | HIV Infections - virology | Humans | Vagina | Antibody Affinity - immunology | Membrane Proteins - immunology | Glycosylation | Mucous Membrane - metabolism | HIV Infections - immunology | HIV-1 - immunology | Immunoglobulin Fc Fragments - immunology | HIV Antibodies - immunology | Mucous Membrane - immunology | Immunoglobulin G - immunology | Protein Binding | Female | Mucus - metabolism | Membrane Proteins - metabolism | CA-125 Antigen - metabolism | HIV Infections - metabolism | HIV | mucin | Antibody glycosylation | mucus
RESPONSES | FC-GAMMA-RIII | SURFACE | IMMUNOGLOBULIN | GLYCOFORMS | IGG-FC | GLYCOSYLATION | IMMUNOLOGY | EXPRESSION | VIRION CAPTURE | ANTIGEN | HIV Antibodies - metabolism | CA-125 Antigen - immunology | Mucous Membrane - virology | Immunoglobulin Fc Fragments - metabolism | HIV Infections - virology | Humans | Vagina | Antibody Affinity - immunology | Membrane Proteins - immunology | Glycosylation | Mucous Membrane - metabolism | HIV Infections - immunology | HIV-1 - immunology | Immunoglobulin Fc Fragments - immunology | HIV Antibodies - immunology | Mucous Membrane - immunology | Immunoglobulin G - immunology | Protein Binding | Female | Mucus - metabolism | Membrane Proteins - metabolism | CA-125 Antigen - metabolism | HIV Infections - metabolism | HIV | mucin | Antibody glycosylation | mucus
Journal Article
Pediatric Research, ISSN 0031-3998, 2018, Volume 86, Issue 3, pp. 339 - 347
BACKGROUND: Low birth weight in term-born individuals correlates with adverse cardiometabolic outcomes; excess glucocorticoid exposure has been linked to these...
DEHYDROEPIANDROSTERONE-SULFATE | PAIN | DISEASE | PEDIATRICS | WEIGHT-GAIN | BIRTH | FETAL | STRESS | SALIVARY | CORTISOL
DEHYDROEPIANDROSTERONE-SULFATE | PAIN | DISEASE | PEDIATRICS | WEIGHT-GAIN | BIRTH | FETAL | STRESS | SALIVARY | CORTISOL
Journal Article
The Journal of Pediatrics, ISSN 0022-3476, 05/2019, Volume 208, pp. 156 - 162.e5
To describe discordance in antenatal corticosteroid use and resuscitation following extremely preterm birth and its relationship with infant survival and...
MORTALITY | SURVIVAL | MORBIDITY | OBSTETRICIANS | INFANTS | PEDIATRICS | NEURODEVELOPMENTAL OUTCOMES | ASSOCIATION | INTENSIVE-CARE | Corticosteroids | Child development | Infants (Premature) | Obstetrics | Analysis | Index Medicus | Abridged Index Medicus
MORTALITY | SURVIVAL | MORBIDITY | OBSTETRICIANS | INFANTS | PEDIATRICS | NEURODEVELOPMENTAL OUTCOMES | ASSOCIATION | INTENSIVE-CARE | Corticosteroids | Child development | Infants (Premature) | Obstetrics | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
Hepatology, ISSN 0270-9139, 09/2015, Volume 62, Issue 3, pp. 932 - 954
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | GENOTYPE 1 | UNITED-STATES | TREATMENT-NAIVE | ANTIVIRAL THERAPY | SOFOSBUVIR PLUS RIBAVIRIN | TREATMENT-EXPERIENCED PATIENTS | LIVER FIBROSIS | OPEN-LABEL | GASTROENTEROLOGY & HEPATOLOGY | Hepacivirus - drug effects | Liver Neoplasms - prevention & control | Liver Neoplasms - virology | Hepacivirus - isolation & purification | Hepatitis C - drug therapy | Risk Assessment | Mandatory Testing - standards | Humans | Male | Evidence-Based Medicine | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Disease Progression | Disease Transmission, Infectious - prevention & control | Hepatitis C - diagnosis | Societies, Medical | Hepatitis C - epidemiology | Adult | Female | Hepatitis C, Chronic - epidemiology | Patient Education as Topic | Practice Guidelines as Topic
Journal Article
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 03/2009, Volume 98, Issue 3, pp. 1198 - 1198
Journal Article
Molecular Ecology, ISSN 0962-1083, 07/2016, Volume 25, Issue 13, pp. 3033 - 3047
Journal Article
11.
Full Text
Abstracts of the HIV Research for Prevention Meeting, HIVR4P, 21-25 October, 2018, Madrid
AIDS Research and Human Retroviruses, ISSN 0889-2229, 10/2018, Volume 34, Issue S1, pp. 1 - 407
Journal Article
2014, 1, ISBN 9781906093990, xvi, 163
Creating Social Value focuses on the motivations and preoccupations of entrepreneurial leaders as they look to activate change within their companies, in their...
Industries | Social aspects | Social entrepreneurship | Corporate Social Responsibility & Business Ethics | Environment & Business | Corporations | Social responsibility of business | Moral and ethical aspects | Social values
Industries | Social aspects | Social entrepreneurship | Corporate Social Responsibility & Business Ethics | Environment & Business | Corporations | Social responsibility of business | Moral and ethical aspects | Social values
Book
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 12/2010, Volume 54, Issue 12, pp. 4999 - 5003
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit...
THERAPY | EFFICACY | HIV-1 INTEGRASE | SAFETY | TOLERABILITY | MK-0518 | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | RANDOMIZED CONTROLLED-TRIAL | INTEGRASE INHIBITOR | HIV Seronegativity | Anti-Retroviral Agents - pharmacokinetics | Humans | Middle Aged | Pyrrolidinones - pharmacokinetics | Male | Young Adult | Drug Interactions | Adolescent | Adult | Female | Antacids - pharmacology | Raltegravir Potassium | Drugs | Metals | Immunodeficiency | Cations | Pharmacokinetics | Antacids | Vitamins | Food | Pharmacology
THERAPY | EFFICACY | HIV-1 INTEGRASE | SAFETY | TOLERABILITY | MK-0518 | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | RANDOMIZED CONTROLLED-TRIAL | INTEGRASE INHIBITOR | HIV Seronegativity | Anti-Retroviral Agents - pharmacokinetics | Humans | Middle Aged | Pyrrolidinones - pharmacokinetics | Male | Young Adult | Drug Interactions | Adolescent | Adult | Female | Antacids - pharmacology | Raltegravir Potassium | Drugs | Metals | Immunodeficiency | Cations | Pharmacokinetics | Antacids | Vitamins | Food | Pharmacology
Journal Article
Phlebology, ISSN 0268-3555, 3/2012, Volume 27, Issue 2, pp. 101 - 101
Journal Article